Emgrast 300mcg Injection

About

Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF), a glycoprotein that plays a crucial role in regulating the production, proliferation, differentiation, and release of neutrophils from the bone marrow. Its primary clinical application is to reduce the incidence and duration of severe neutropenia, and consequently the risk of febrile neutropenia and infection, in patients undergoing myelosuppressive chemotherapy for non-myeloid malignancies. Furthermore, filgrastim is indicated for patients with severe chronic neutropenia, including congenital, cyclic, and idiopathic neutropenia, to decrease the incidence and severity of infections. It is also vital for the mobilization of peripheral blood progenitor cells for autologous or allogeneic transplantation, and in patients with AIDS receiving zidovudine to treat neutropenia.

Uses

• Reduction of infection incidence in chemotherapy-induced neutropenia.
• Treatment of severe chronic neutropenia.
• Mobilization of peripheral blood progenitor cells.
• Neutropenia associated with bone marrow transplantation.

Directions For Use

Administer as a subcutaneous injection or intravenous infusion as directed by your healthcare provider. Do not shake the vial.

Benefits

• Reduces risk of infection in chemotherapy patients.
• Shortens duration of severe neutropenia.
• Enhances recovery of white blood cells.
• Supports bone marrow transplantation procedures.
• Improves immune system function.
• Helps manage chronic neutropenic conditions.

Side Effects

• Bone pain
• Muscle pain
• Headache
• Fatigue
• Nausea
• Vomiting
• Diarrhea
• Rash
• Injection site reactions
• Splenomegaly (rare)
• Allergic reactions (rare)
• Acute respiratory distress syndrome (rare)

Safety Measures

• Alcohol - No specific contraindication, but general health advice regarding alcohol consumption should be followed.
• Pregnancy - Use only if clearly needed and potential benefits outweigh risks, as animal studies show adverse effects.
• Breastfeeding - Caution is advised; it is unknown if filgrastim is excreted in human milk.
• Liver - No specific dose adjustment required for liver impairment, but monitor patients closely.
• Kidney - No specific dose adjustment required for kidney impairment, but monitor patients closely.
• Lung - Use with caution in patients with pre-existing lung conditions, as pulmonary adverse reactions have been reported.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.